TY - JOUR
T1 - Postoperative Urinary Retention in Modern Rapid Recovery Total Joint Arthroplasty
AU - Bracey, Daniel N.
AU - Barry, Kawsu
AU - Khanuja, Harpal S.
AU - Hegde, Vishal
N1 - Funding Information:
Khanuja or an immediate family member serves as a paid consultant to Smith & Nephew. Khanuja and Hegde receive fellowship support from OMeGA Medical Grants and from Smith & Nephew. Neither of the following authors nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Bracey and Barry.
Publisher Copyright:
© American Academy of Orthopaedic Surgeons.
PY - 2022/5/15
Y1 - 2022/5/15
N2 - Postoperative urinary retention (POUR) is a disruptive complication after modern rapid recovery total joint arthroplasty. This review aims to synthesize the recent literature on POUR in the setting of total joint arthroplasty. The incidence of POUR ranges from 5.5% to 46.3%. The lack of a standardized definition of POUR accounts for some of this variability. Risk factors previously associated with the development of POUR include increasing age, male sex, benign prostatic hyperplasia, use of bupivacaine and intrathecal morphine in spinal anesthesia, glycopyrrolate, and volume of intraoperative intravenous fluid administered. Predictive scoring assessments, such as the International Prostate Symptom Score and a newer predictive nomogram, have not been adequately validated by high-quality studies. The treatment of POUR comprises either intermittent or indwelling urethral catheterization. Higher quality prospective studies are needed to allow for the standardization of all aspects of POUR from its diagnostic criteria to its treatment.
AB - Postoperative urinary retention (POUR) is a disruptive complication after modern rapid recovery total joint arthroplasty. This review aims to synthesize the recent literature on POUR in the setting of total joint arthroplasty. The incidence of POUR ranges from 5.5% to 46.3%. The lack of a standardized definition of POUR accounts for some of this variability. Risk factors previously associated with the development of POUR include increasing age, male sex, benign prostatic hyperplasia, use of bupivacaine and intrathecal morphine in spinal anesthesia, glycopyrrolate, and volume of intraoperative intravenous fluid administered. Predictive scoring assessments, such as the International Prostate Symptom Score and a newer predictive nomogram, have not been adequately validated by high-quality studies. The treatment of POUR comprises either intermittent or indwelling urethral catheterization. Higher quality prospective studies are needed to allow for the standardization of all aspects of POUR from its diagnostic criteria to its treatment.
UR - http://www.scopus.com/inward/record.url?scp=85131124033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131124033&partnerID=8YFLogxK
U2 - 10.5435/JAAOS-D-21-00963
DO - 10.5435/JAAOS-D-21-00963
M3 - Review article
C2 - 35213416
AN - SCOPUS:85131124033
SN - 1067-151X
VL - 30
SP - 443
EP - 447
JO - Journal of the American Academy of Orthopaedic Surgeons
JF - Journal of the American Academy of Orthopaedic Surgeons
IS - 10
ER -